Curcumin acts via transient receptor potential vanilloid-1 receptors to inhibit gut nociception and reverses visceral hyperalgesia

Neurogastroenterology and Motility

Volumn 25, Issue 6, 2013, Pages

  Zhi, L ^a   Dong, L ^a   Kong, D ^a   Sun, B ^a   Sun, Q ^a   Grundy, D ^b   Zhang, G ^a   Rong, W ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

Curcumin; Functional gastrointestinal diseases; Transient receptor potential vanilloid 1; Visceral pain

Indexed keywords

CALCIUM; CAPSAICIN; CURCUMIN; TRINITROBENZENESULFONIC ACID; VANILLOID RECEPTOR 1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINOCICEPTION; ARTICLE; CALCIUM TRANSPORT; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; ELECTROMYOGRAM; HYPERALGESIA; JEJUNUM; MALE; MOUSE; NERVE CELL; NOCICEPTION; NONHUMAN; PRIORITY JOURNAL; RAT; SPINAL GANGLION; VISCERA;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CURCUMIN; HYPERALGESIA; MALE; MICE; MICE, KNOCKOUT; NEURONS, AFFERENT; NOCICEPTION; RATS; RATS, SPRAGUE-DAWLEY; TRPV CATION CHANNELS; VISCERA;

EID: 84878014222     PISSN: 13501925     EISSN: 13652982     Source Type: Journal    
DOI: 10.1111/nmo.12145     Document Type: Article

References (50)

1. Mayer EA, Gebhart GF. Basic and clinical aspects of visceral hyperalgesia. Gastroenterology 1994; 107: 271-93.
2. Li Y. Sensory signal transduction in the vagal primary afferent neurons. Curr Med Chem 2007; 14: 2554-63.
3. Kirkup AJ, Brunsden AM, Grundy D. Receptors and transmission in the brain-gut axis: potential for novel therapies. I. Receptors on visceral afferents. Am J Physiol Gastrointest Liver Physiol 2001; 280: G787-94.
4. Anavi-Goffer S, McKay NG, Ashford ML, Coutts AA. Vanilloid receptor type 1-immunoreactivity is expressed by intrinsic afferent neurones in the guinea-pig myenteric plexus. Neurosci Lett 2002; 319: 53-7.
5. Caterina MJ, Schumacher MA, Tominaga M, Rosen TA, Levine JD, Julius D. The capsaicin receptor: a heat-activated ion channel in the pain pathway. Nature 1997; 389: 816-24.
6. Hayes P, Meadows HJ, Gunthorpe MJ et al. Cloning and functional expression of a human orthologue of rat vanilloid receptor-1. Pain 2000; 88: 205-15.
7. Kwak JY, Jung JY, Hwang SW, Lee WT, Oh U. A capsaicin-receptor antagonist, capsazepine, reduces inflammation-induced hyperalgesic responses in the rat: evidence for an endogenous capsaicin-like substance. Neuroscience 1998; 86: 619-26.
8. Patterson LM, Zheng H, Ward SM, Berthoud HR. Vanilloid receptor (VR1) expression in vagal afferent neurons innervating the gastrointestinal tract. Cell Tissue Res 2003; 311: 277-87.
9. Tominaga M, Caterina MJ, Malmberg AB et al. The cloned capsaicin receptor integrates multiple pain-producing stimuli. Neuron 1998; 21: 531-43.
10. Caterina MJ, Julius D. The vanilloid receptor: a molecular gateway to the pain pathway. Annu Rev Neurosci 2001; 24: 487-517.
11. Caterina MJ, Rosen TA, Tominaga M, Brake AJ, Julius D. A capsaicin-receptor homologue with a high threshold for noxious heat. Nature 1999; 398: 436-41.
12. Olah Z, Karai L, Iadarola MJ. Anandamide activates vanilloid receptor 1 (VR1) at acidic pH in dorsal root ganglia neurons and cells ectopically expressing VR1. J Biol Chem 2001; 276: 31163-70.
13. Jones RC 3rd, Xu L, Gebhart GF. The mechanosensitivity of mouse colon afferent fibers and their sensitization by inflammatory mediators require transient receptor potential vanilloid 1 and acid-sensing ion channel 3. J Neurosci 2005; 25: 10981-9.
14. Rong W, Hillsley K, Davis JB, Hicks G, Winchester WJ, Grundy D. Jejunal afferent nerve sensitivity in wild-type and TRPV1 knockout mice. J Physiol 2004; 560: 867-81.
15. De Schepper HU, De Man JG, Ruyssers NE et al. TRPV1 receptor signaling mediates afferent nerve sensitization during colitis-induced motility disorders in rats. Am J Physiol Gastrointest Liver Physiol 2008; 294: G245-53.
16. Fujino K, Takami Y, De la Fuente SG, Ludwig KA, Mantyh CR. Inhibition of the vanilloid receptor subtype-1 attenuates TNBS-colitis. J Gastrointest Surg 2004; 8: 842-7. Discussion 847-8.
17. Kihara N, de la Fuente SG, Fujino K, Takahashi T, Pappas TN, Mantyh CR. Vanilloid receptor-1 containing primary sensory neurones mediate dextran sulphate sodium induced colitis in rats. Gut 2003; 52: 713-9.
18. Kimball ES, Wallace NH, Schneider CR, D'Andrea MR, Hornby PJ. Vanilloid receptor 1 antagonists attenuate disease severity in dextran sulphate sodium-induced colitis in mice. Neurogastroenterol Motil 2004; 16: 811-8.
19. Yiangou Y, Facer P, Dyer NH et al. Vanilloid receptor 1 immunoreactivity in inflamed human bowel. Lancet 2001; 357: 1338-9.
20. Garle MJ, Knight A, Downing AT, Jassi KL, Clothier RH, Fry JR. Stimulation of dichlorofluorescin oxidation by capsaicin and analogues in RAW 264 monocyte/macrophages: lack of involvement of the vanilloid receptor. Biochem Pharmacol 2000; 59: 563-72.
21. Sharma RA, Gescher AJ, Steward WP. Curcumin: the story so far. Eur J Cancer 2005; 41: 1955-68.
22. Sandur SK, Pandey MK, Sung B et al. Curcumin, demethoxycurcumin, bisdemethoxycurcumin, tetrahydrocurcumin and turmerones differentially regulate anti-inflammatory and anti-proliferative responses through a ROS-independent mechanism. Carcinogenesis 2007; 28: 1765-73.
23. Daniel S, Limson JL, Dairam A, Watkins GM, Daya S. Through metal binding, curcumin protects against lead- and cadmium-induced lipid peroxidation in rat brain homogenates and against lead-induced tissue damage in rat brain. J Inorg Biochem 2004; 98: 266-75.
24. Lee KH, Ab Aziz FH, Syahida A et al. Synthesis and biological evaluation of curcumin-like diarylpentanoid analogues for anti-inflammatory, antioxidant and anti-tyrosinase activities. Eur J Med Chem 2009; 44: 3195-200.
25. Naidu KA, Thippeswamy NB. Inhibition of human low density lipoprotein oxidation by active principles from spices. Mol Cell Biochem 2002; 229: 19-23.
26. Patro BS, Rele S, Chintalwar GJ, Chattopadhyay S, Adhikari S, Mukherjee T. Protective activities of some phenolic 1, 3-diketones against lipid peroxidation: possible involvement of the 1, 3-diketone moiety. Chem Bio Chem 2002; 3: 364-70.
27. Li CJ, Zhang LJ, Dezube BJ, Crumpacker CS, Pardee AB. Three inhibitors of type 1 human immunodeficiency virus long terminal repeat-directed gene expression and virus replication. Proc Natl Acad Sci U S A 1993; 90: 1839-42.
28. Aggarwal BB, Kumar A, Bharti AC. Anticancer potential of curcumin: preclinical and clinical studies. Anticancer Res 2003; 23: 363-98.
29. Sharma S, Kulkarni SK, Agrewala JN, Chopra K. Curcumin attenuates thermal hyperalgesia in a diabetic mouse model of neuropathic pain. Eur J Pharmacol 2006; 536: 256-61.
30. Mittal N, Joshi R, Hota D, Chakrabarti A. Evaluation of antihyperalgesic effect of curcumin on formalin-induced orofacial pain in rat. Phytother Res 2009; 23: 507-12.
31. Tajik H, Tamaddonfard E, Hamzeh-Gooshchi N. The effect of curcumin (active substance of turmeric) on the acetic acid-induced visceral nociception in rats. Pak J Biol Sci 2008; 11: 312-4.
32. Bereswill S, Munoz M, Fischer A et al. Anti-inflammatory effects of resveratrol, curcumin and simvastatin in acute small intestinal inflammation. PLoS One 2010; 5: e15099.
33. Murphy EA, Davis JM, McClellan JL, Gordon BT, Carmichael MD. Curcumin's effect on intestinal inflammation and tumorigenesis in the ApcMin/+ mouse. J Interferon Cytokine Res 2011; 31: 219-26.
34. Salh B, Assi K, Templeman V et al. Curcumin attenuates DNB-induced murine colitis. Am J Physiol Gastrointest Liver Physiol 2003; 285: G235-43.
35. Sugimoto K, Hanai H, Tozawa K et al. Curcumin prevents and ameliorates trinitrobenzene sulfonic acid-induced colitis in mice. Gastroenterology 2002; 123: 1912-22.
36. Ukil A, Maity S, Karmakar S, Datta N, Vedasiromoni JR, Das PK. Curcumin, the major component of food flavour turmeric, reduces mucosal injury in trinitrobenzene sulphonic acid-induced colitis. Br J Pharmacol 2003; 139: 209-18.
37. Martelli L, Ragazzi E, di Mario F et al. A potential role for the vanilloid receptor TRPV1 in the therapeutic effect of curcumin in dinitrobenzene sulphonic acid-induced colitis in mice. Neurogastroenterol Motil 2007; 19: 668-74.
38. Yeon KY, Kim SA, Kim YH et al. Curcumin produces an antihyperalgesic effect via antagonism of TRPV1. J Dent Res 2010; 89: 170-4.
39. Holzer P. Transient receptor potential (TRP) channels as drug targets for diseases of the digestive system. Pharmacol Ther 2011; 131: 142-70.
40. Bilmen JG, Khan SZ, Javed MH, Michelangeli F. Inhibition of the SERCA Ca2+ pumps by curcumin. Curcumin putatively stabilizes the interaction between the nucleotide-binding and phosphorylation domains in the absence of ATP. Eur J Biochem 2001; 268: 6318-27.
41. Chen HW, Huang HC. Effect of curcumin on cell cycle progression and apoptosis in vascular smooth muscle cells. Br J Pharmacol 1998; 124: 1029-40.
42. Dyer JL, Khan SZ, Bilmen JG et al. Curcumin: a new cell-permeant inhibitor of the inositol 1, 4, 5-trisphosphate receptor. Cell Calcium 2002; 31: 45-52.
43. Liu JY, Lin SJ, Lin JK. Inhibitory effects of curcumin on protein kinase C activity induced by 12-O-tetradecanoyl-phorbol-13-acetate in NIH 3T3 cells. Carcinogenesis 1993; 14: 857-61.
44. 2+ signaling. Biochem Pharmacol 1999; 58: 1167-72.
45. Zhang F, Altorki NK, Mestre JR, Subbaramaiah K, Dannenberg AJ. Curcumin inhibits cyclooxygenase-2 transcription in bile acid- and phorbol ester-treated human gastrointestinal epithelial cells. Carcinogenesis 1999; 20: 445-51.
46. Zhao X, Xu Y, Zhao Q, Chen CR, Liu AM, Huang ZL. Curcumin exerts antinociceptive effects in a mouse model of neuropathic pain: descending monoamine system and opioid receptors are differentially involved. Neuropharmacology 2012; 62: 843-54.
47. LaMotte RH, Lundberg LE, Torebjork HE. Pain, hyperalgesia and activity in nociceptive C units in humans after intradermal injection of capsaicin. J Physiol 1992; 448: 749-64.
48. Simone DA, Baumann TK, Collins JG, LaMotte RH. Sensitization of cat dorsal horn neurons to innocuous mechanical stimulation after intradermal injection of capsaicin. Brain Res 1989; 486: 185-9.
49. Torebjork HE, Lundberg LE, LaMotte RH. Central changes in processing of mechanoreceptive input in capsaicin-induced secondary hyperalgesia in humans. J Physiol 1992; 448: 765-80.
50. Walker KM, Urban L, Medhurst SJ et al. The VR1 antagonist capsazepine reverses mechanical hyperalgesia in models of inflammatory and neuropathic pain. J Pharmacol Exp Ther 2003; 304: 56-62.